Compare INOD & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INOD | CAPR |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | United States | United States |
| Employees | 3000 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1996 | 2011 |
| Metric | INOD | CAPR |
|---|---|---|
| Price | $90.50 | $29.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $100.00 | $44.63 |
| AVG Volume (30 Days) | ★ 2.4M | 988.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.37 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $86,775,000.00 | N/A |
| Revenue This Year | $38.42 | N/A |
| Revenue Next Year | $27.03 | $3.31 |
| P/E Ratio | $212.98 | ★ N/A |
| Revenue Growth | ★ 9.84 | N/A |
| 52 Week Low | $33.79 | $4.30 |
| 52 Week High | $114.77 | $40.37 |
| Indicator | INOD | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 74.76 | 41.93 |
| Support Level | $39.15 | $26.06 |
| Resistance Level | $93.82 | $30.06 |
| Average True Range (ATR) | 8.35 | 2.09 |
| MACD | 5.53 | -0.55 |
| Stochastic Oscillator | 68.68 | 19.05 |
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.